5-(4-bromophenyl)-4-methyl-1H-pyrazole | 208511-70-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-(4-bromophenyl)-4-methyl-1H-pyrazole
• CAS: 208511-70-0
• 化学式: C₁₀H₉BrN₂
• 分子量: 237.099
• InChiKey: ICJRBQCMYWPUHG-UHFFFAOYSA-N

物化性质

• 沸点：
  372.1±27.0 °C(Predicted)
• 密度：
  1.493±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  28.7
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  5-(4-bromophenyl)-4-methyl-1H-pyrazole 在 双(乙腈)氯化钯(II) 、 caesium carbonate 、 2-二环己基磷-2,4,6-三异丙基联苯 作用下， 以 水 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 5.58h， 生成 3-[4-(2-Cyclopropylethynyl)phenyl]-4-methyl-1-(oxan-2-ylmethyl)pyrazole
  参考文献：
  名称：

  [EN] GPR84 ANTAGONISTS AND USES THEREOF
  [FR] ANTAGONISTES DE GPR84 ET LEURS UTILISATIONS

  摘要：

  本发明提供了式（I）化合物，其组成物以及使用它们来抑制GPR84和治疗GPR84介导的疾病的方法。

  公开号：

  WO2022167457A1
• 作为产物：
  描述：

  1-(4-bromophenyl)-3-(dimethylamino)-2-methylprop-2-en-1-one 在 一水合肼 作用下， 以 乙醇 为溶剂， 以94 %的产率得到5-(4-bromophenyl)-4-methyl-1H-pyrazole
  参考文献：
  名称：

  [EN] GPR84 ANTAGONISTS AND USES THEREOF
  [FR] ANTAGONISTES DE GPR84 ET LEURS UTILISATIONS

  摘要：

  本发明提供了式（I）化合物，其组成物以及使用它们来抑制GPR84和治疗GPR84介导的疾病的方法。

  公开号：

  WO2022167457A1

文献信息

• A general, [1+4] approach to the synthesis of 3(5)-substituted pyrazoles from aldehydes
  作者：Nicoletta Almirante、Alberto Cerri、Giorgio Fedrizzi、Giuseppe Marazzi、Marco Santagostino

  DOI：10.1016/s0040-4039(98)00472-9

  日期：1998.5

  A new, one-pot preparation of 3(5)-substituted-1H-pyrazole is described that employs Horner-Emmons reaction of aldehydes with dianion of novel phosphonate 1 and proceeds through cyclization of N-sodium salt of α,β-unsaturated tosylhydrazones 2.

  描述了一种新的一锅法制备的3（5）-取代的-1H-吡唑，该制剂利用醛与新型膦酸酯1的二价阴离子进行霍纳-埃蒙斯反应，并通过环化α，β-不饱和甲苯磺酰N的N-钠盐进行2。
• β-Tosylhydrazono Phosphonates in Organic Synthesis. An Unambiguous Entry to Polysubstituted Pyrazoles
  作者：N. Almirante、A. Benicchio、A. Cerri、G. Fedrizzi、G. Marazzi、M. Santagostino

  DOI：10.1055/s-1999-2608

  日期：1999.3

  β-Tosylhydrazono phosphonates are novel, bifunctional reagents which were used for a concise approach to a wide range of polysubstituted pyrazoles in a single operation from aromatic and aliphatic aldehydes.

  δ-对甲苯磺酰基肼基膦酸盐是一种新型的双功能试剂，用于以芳香族和脂肪族醛为原料，通过一次操作简便地制备出多种多取代吡唑。
• Novel tricyclic pyrazole BRAF inhibitors with imidazole or furan central scaffolds
  作者：Dan Niculescu-Duvaz、Ion Niculescu-Duvaz、Bart M.J.M. Suijkerbuijk、Delphine Ménard、Alfonso Zambon、Arnaud Nourry、Lawrence Davies、Helen A. Manne、Frank Friedlos、Lesley Ogilvie、Douglas Hedley、Andrew K. Takle、David M. Wilson、Jean-Francois Pons、Tom Coulter、Ruth Kirk、Neus Cantarino、Steven Whittaker、Richard Marais、Caroline J. Springer

  DOI：10.1016/j.bmc.2010.06.031

  日期：2010.9

  V-RAF murine sarcoma viral oncogene homolog B1 (BRAF) is a serine/threonine-specific protein kinase that is mutated with high frequency in cutaneous melanoma, and many other cancers. Inhibition of mutant BRAF is an attractive therapeutic approach for the treatment of melanoma. A triarylimidazole BRAF inhibitor bearing a phenylpyrazole group (dimethyl-[2-(4-5-[4-(1H-pyrazol-3-yl)-phenyl]-4-pyridin- 4-yl-1H-imidazol-2-yl}-phenoxy)-ethyl]-amine, 1a) was identified as an active BRAF inhibitor. Based on this starting point, we synthesized a series of analogues leading to the discovery of 6-2-[4-(4-methylpiperazin- 1-yl)-phenyl]-5-pyridin-4-yl-3H-imidazol-4-yl}-2,4-dihydro-indeno[1,2-c]pyrazole (1j), with nanomolar activity in three assays: inhibition of purified mutant BRAF activity in vitro; inhibition of oncogenic BRAF-driven extracellular regulated kinase (ERK) activation in BRAF mutant melanoma cell lines; and inhibition of proliferation in these cells. (C) 2010 Elsevier Ltd. All rights reserved.
• NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A
  申请人：AbbVie Inc.

  公开号：EP2922842A2

  公开（公告）日：2015-09-30
• [EN] NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A<br/>[FR] NOUVEAUX COMPOSÉS INHIBITEURS DE PHOSPHODIESTÉRASE DE TYPE 10A
  申请人：ABBVIE INC

  公开号：WO2014079995A2

  公开（公告）日：2014-05-30

  The present invention relates to compounds of the formula I and their salts etc. which are inhibitors of phosphodiesterase type 10A and to their use for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders wherein Y1 and Y2 are adjacent atoms in Het1, which are independently selected from the group consisting of carbon and nitrogen; k is 0, 1, 2 or 3; Het1 is a bivalent monocyclic 5- or 6-membered heteroaromatic radical, having 1, 2 or 3 heteroatoms or heteroatom moieties selected from O, S, N and N-Ra as ring members, or a bivalent fused bicyclic 8-, 9- or 10-membered heteroaromatic radical, having 1, 2, 3 or 4 heteroatoms or heteroatom moieties selected from O, S, N and N-Ra as ring members; Het2 is inter alia monocyclic 5- or 6-membered hetaryl, having 1, 2 or 3 heteroatoms or heteroatom moieties selected from O, S, N and N-R1a as ring members, Cyc is inter alia optionally substituted monocyclic 5- or 6-membered hetaryl or optionally substituted fused 8-, 9- or 10-membered bicyclic hetaryl; Ar is optionally substituted phenylene or optionally substituted bivalent 6-membered hetaryl; R is attached to a carbon atom of Het1 and inter alia - halogen, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6-alkoxy, C1-C6-fluoroalkyl, C1-C6-fluoroalkoxy, C3-C6-cycloalkyl etc.